These drugs are expected to enter the basic drug list

Pharmaceutical network November 19 - health insurance-based drugs or become agents in the system of chicken ribs, good development but not money-making base drugs the latest news came out yesterday, the national basic drug management methods for comments and discussion meetings in the industry spread.
Next year, the focus of the adjustment of the focus of the drug also came out: 1, infectious diseases, 2, chronic diseases and cancer, tumor slow disease medication; 3, common diseases drug use; 4, disease-led direction, it is true that patients are not available, need to be treated with the disease, to choose the most appropriate range; 5, mainly look at product value, clinical endpoint indicators to improve the long-term quality of life of patients, to cure as a standard.
also made suggestions: 1, the number of base drugs to meet 900: hope that the expansion of the list of basic drugs to 986 hospital staffing ratio requirements.
if the average number of drugs used in each triple-A hospital in the country is calculated, the number of base drugs must meet 900 to meet the policy requirements.
2, let go of restrictions: it is recommended to be able to release the specifications of the base drug catalog restrictions, according to the administration of the dosage form of the dosage pathway, such as injection needles, powder needles and lipid microballs are no longer distinguished, as included.
3, direct access to health insurance: it is recommended that the products included in the list of basic drugs are directly included in the list of health insurance, in order to reflect the value of the base medicine.
4, combined with the evidence of comprehensive drug evaluation: 5, giving priority to the use of more than 1 billion yuan of varieties 6, hope to add more traditional Chinese medicine, so that the proportion of Chinese and Western medicine balanced.
Today, with the two insurance in one, graded diagnosis and treatment, grass-roots equipped with a certain proportion of non-base drugs and other policies, the characteristics of the base drug is no longer obvious, the role of the base drug catalog is invisibly weakened, but it is still one of the enterprises seeking to enter the directory.
Huang Yong, marketing director of Yanjiang Pharmaceutical Industry, to Saibai Blue analysis: In fact, the landing and implementation of the base medicine is more thorough, the use of the basic medicine in each hospital has an administrative level of assessment, but also in line with the hospital's proportion of drugs and medical insurance funds control requirements;
He further explained: some have not yet entered the base drug catalog or quasi-base drug products, because there is no status of the base drug, the entire operating system and agency system for the operation of varieties is more difficult, because the hospitals for the base drug ratio has rigid demand;
base drug catalog overlay with volume procurement, agent crisis from the focus of this adjustment of the focus of the drug, there is clinical value of high-priced drugs can also be considered to be included in the base drug catalog, that is to say, the basic drug system has been thinking from? Guaranteed basic? To? To protect clinical value? The adjustment thinking of the base drug catalogue has changed profoundly from a focus on inexpensiveness to a comprehensive consideration of the clinical value of drugs and the benefits of pharmacoeconomics.
In this regard, Huang Yong said: this change of thinking is to a large extent to solve the problem of graded diagnosis and treatment of the base medicine, the past base medicine can only be used at the grass-roots level, grade hospitals can hardly use, so many grade hospital experts prescription to the community, to the county hospital, or back to the local, can not continue to prescribe drugs - grade hospital prescriptions may be non-base drugs.
and the grass-roots are all base drugs, invisibly caused by the graded diagnosis and treatment of the gap, the current adjustment will have a good promotion of graded diagnosis and treatment, but also to promote the stability of the patient's medication.
in this drug fair, Saibai Blue learned that agents are most concerned about two: national-based varieties and national talk varieties.
countries are clear that national-based varieties and national-based varieties should be given priority procurement, so each hospital's pharmaceutical conference is clear, the meeting only discussed national-based varieties.
for agents, the greatest value of drugs is to enter the hospital, sales essentially do not need innovation, as long as the hospital naturally has sales.
" whether it is the base medicine, or health insurance, is now basically a must-talk price, or access status is determined by the health insurance payment and price system, and then superimposed with the purchase effect, which will face the decline in the commercial value of drugs.
" Huang Yong frankly: health insurance-based drugs become the agent system of chicken ribs, good development but not money.
He explained: the definition of the base drug itself is product maturity, drug experience mature, less adverse reactions, this is the basic principle of doing the base medicine, because it is to solve the interests of the vast majority of the people medical needs, the exclusive variety of basic drugs is after all a minority;
and into the base medicine and health insurance, facing the province's volume and the national volume of the problem, the volume will certainly increase, if entered the province's sales amount ranking top50 or Top100, according to the logic of volume procurement, it is likely to be taken volume, direct supply of enterprises, agents on the basic out - this is a combination of fist logic.
Huang Yong said.
does the drug squeeze the non-base drug space? According to the conference spread the news: according to the current national average of 1500 varieties of drugs in each triple-A hospital, the number of base drugs 900 to meet the policy requirements.
in the context of 986, will this greatly squeeze the survival space of non-base pharmaceutical products? Huang Yong calculated a set of figures: 1500 varieties of grade hospitals, at least 900 are base drugs, then the remaining 600 non-base drugs, according to three or seven prescriptions, 30% are Chinese medicine, 70% are chemical drugs, then chemical drugs are only about 400, and then remove two or three hundred new global compounds and original research enterprises and foreign pharmaceutical companies of new special drugs, leaving only one or two hundred opportunities for domestic enterprises to survive.
, it should be noted that economy is a major consideration in whether medicines will be included in the list of essential medicines.
The treatment of tumors is increasingly convergeing towards the treatment of chronic diseases, and basic medical institutions should be equipped with more and more oncology drugs for patients to use, but overall, the price of cancer drugs is high and are exclusive products, whether more cancer drugs will be included in the base drugs in the future is still worth measuring.
The concept of the base drug itself, that is, wide coverage, huimin, low price, drug maturity, less adverse reactions, if just listed new cancer drugs, there is no strong incentive to reduce prices, even if into the base drug, but also contrary to the original intention of the base drug.
Huang Yong believes that the varieties over the patent period, if it is the original research enterprises or domestic enterprises, their research and development and approval costs have basically earned back.
are now mainly industrial costs, so they have the prerequisites to reduce prices after entering the base drug.
new drugs still require a long payback period, it is difficult to have the incentive to cut prices, and do not need to enter the base drug.
, domestic generic drugs are more mature, the efficacy has been confirmed, there is room for price reduction over-patented drugs, will be more likely to enter the base drug.
with the national attention to the base drug on the agenda, will further strengthen the role of the base drug catalog, which may also make the future pattern of clinical drug use a new round of shuffle.
。